Thomas Stock

1.0k total citations
15 papers, 726 citations indexed

About

Thomas Stock is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Thomas Stock has authored 15 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Rheumatology, 4 papers in Hematology and 4 papers in Immunology. Recurrent topics in Thomas Stock's work include Rheumatoid Arthritis Research and Therapies (5 papers), Autoimmune and Inflammatory Disorders Research (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Thomas Stock is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (5 papers), Autoimmune and Inflammatory Disorders Research (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Thomas Stock collaborates with scholars based in United States, Norway and Japan. Thomas Stock's co-authors include Charles A. Mebus, Pankaj Gupta, Bradley J. Bloom, Xin Wang, Won Park, Manisha Lamba, Christine Alvey, Joseph Kushner, Piet H. van der Graaf and Gianluca Nucci and has published in prestigious journals such as Annals of the Rheumatic Diseases, Psychopharmacology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Thomas Stock

15 papers receiving 705 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Stock United States	11	158	150	130	114	92	15	726
Barry Ticho United States	14	129 0.8×	244 1.6×	157 1.2×	64 0.6×	418 4.5×	27	1.5k
June Mason Germany	18	23 0.1×	290 1.9×	82 0.6×	23 0.2×	47 0.5×	24	1.0k
Yilin Fan China	14	6 0.0×	182 1.2×	114 0.9×	15 0.1×	118 1.3×	32	537
Wenrui Ye China	13	15 0.1×	199 1.3×	76 0.6×	14 0.1×	127 1.4×	34	960
Chang Xu United States	20	13 0.1×	300 2.0×	93 0.7×	312 2.7×	126 1.4×	59	1.1k
Kim P. Gallagher United States	25	36 0.2×	159 1.1×	64 0.5×	8 0.1×	9 0.1×	69	1.6k
Guilaine Boursier France	14	6 0.0×	193 1.3×	127 1.0×	63 0.6×	14 0.2×	50	551
Jeffrey C. Miecznikowski United States	18	4 0.0×	509 3.4×	71 0.5×	16 0.1×	87 0.9×	59	1.2k
Jianwen Chen China	19	11 0.1×	347 2.3×	30 0.2×	18 0.2×	49 0.5×	46	969

Countries citing papers authored by Thomas Stock

Since Specialization

Citations

This map shows the geographic impact of Thomas Stock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Stock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Stock more than expected).

Fields of papers citing papers by Thomas Stock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Stock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Stock. The network helps show where Thomas Stock may publish in the future.

Co-authorship network of co-authors of Thomas Stock

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Stock. A scholar is included among the top collaborators of Thomas Stock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Stock. Thomas Stock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Delgado, Julio, et al.. (2021). The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. ESMO Open. 6(1). 100031–100031. 10 indexed citations

Kushner, Joseph, Manisha Lamba, Thomas Stock, et al.. (2019). Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology. European Journal of Pharmaceutical Sciences. 147. 105200–105200. 17 indexed citations

Tanaka, Yoshiya, Naonobu Sugiyama, Shigeyuki Toyoizumi, et al.. (2018). Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. Lara D. Veeken. 58(1). 70–79. 14 indexed citations

Ruperto, Nicolino, Hermine I. Brunner, Zbigniew Żuber, et al.. (2017). Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatric Rheumatology. 15(1). 86–86. 63 indexed citations

Ripp, Sharon L., et al.. (2017). In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor. Clinical Pharmacology in Drug Development. 7(3). 244–255. 3 indexed citations

Stock, Thomas, Dona Fleishaker, Xin Wang, Arnab Mukherjee, & Charles A. Mebus. (2017). Improved disease activity with fosdagrocorat (PF‐04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study. International Journal of Rheumatic Diseases. 20(8). 960–970. 23 indexed citations

Lamba, Manisha, Rong Wang, Tracey Fletcher, et al.. (2016). Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food. The Journal of Clinical Pharmacology. 56(11). 1362–1371. 62 indexed citations

Lamba, M., Tracey Fletcher, Christine Alvey, et al.. (2014). THU0143 Pharmacokinetics, Bioavailability and Safety of A Modified Release Once Daily Formulation of Tofacitinib in Healthy Volunteers. Annals of the Rheumatic Diseases. 73. 228–228. 2 indexed citations

Wong, Dean F., Hiroto Kuwabara, James Robert Brašić, et al.. (2013). Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology. 229(2). 245–252. 25 indexed citations

10.

Milligan, Peter A., B Marchant, Steven W. Martin, et al.. (2013). Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development. Clinical Pharmacology & Therapeutics. 93(6). 502–514. 174 indexed citations

11.

Stock, Thomas, Bradley J. Bloom, Won Park, et al.. (2012). Efficacy and Safety of CE-224,535, an Antagonist of P2X₇Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate. The Journal of Rheumatology. 39(4). 720–727. 203 indexed citations

12.

Fleishaker, Dona, Xin Wang, Sujatha Menon, et al.. (2012). Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Research & Therapy. 14(1). R11–R11. 51 indexed citations

13.

Saasen, Arild, Tor Henry Omland, Eric Villard, et al.. (2009). Automatic Measurement of Drilling Fluid and Drill-Cuttings Properties. SPE Drilling & Completion. 24(4). 611–625. 47 indexed citations

14.

Saasen, Arild, Tor Henry Omland, Eric Villard, et al.. (2008). Automatic Measurement of Drilling Fluid and Drill Cuttings Properties. 31 indexed citations

15.

Lindauer, James M., et al.. (2007). Automated QT measurements for moxifloxicin and physiologic challenge in healthy volunteers. Journal of Electrocardiology. 40(6). S32–S32. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact